Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada.
Division of Dermatology, College of Medicine, Shaqra University, Dawadmi, Saudi Arabia.
J Cutan Med Surg. 2023 May-Jun;27(3):236-240. doi: 10.1177/12034754231167140. Epub 2023 Apr 4.
Biological treatments targeting IL-17 are highly efficacious with rapid onset of action in psoriasis. Cutaneous adverse events are associated with different biological treatments, including paradoxical psoriasis and eczematous reactions. Brodalumab was previously suggested as an alternative treatment option in psoriasis patients who developed dermatitis or paradoxical psoriasis while on a biologic. Here we report three psoriasis patients who developed brodalumab induced eczematous reaction with complete clearance after switching to risankizumab. Early recognition is crucial for appropriate management. We propose switching patients with psoriasis who develop severe eczematous reaction while on a biologic targeting IL-17 to an IL 23 inhibitor due to efficacy in psoriasis and rarely reported eczematous reaction.
针对白细胞介素-17 的生物疗法在银屑病中具有高效性和快速作用。不同的生物疗法与皮肤不良事件相关，包括反常银屑病和湿疹样反应。巴利昔单抗先前被建议作为在接受生物制剂治疗时出现皮炎或反常银屑病的银屑病患者的替代治疗选择。在这里，我们报告了三例银屑病患者，他们在改用 risankizumab 后出现了巴利昔单抗诱导的湿疹样反应，且完全消退。早期识别对于适当的管理至关重要。我们建议将正在接受针对白细胞介素-17 的生物制剂治疗且出现严重湿疹样反应的银屑病患者转换为白细胞介素 23 抑制剂，因为其在银屑病中具有疗效，且湿疹样反应的报告罕见。
